Mark W. Womack Named to Bridgewest Perth Pharma Pty Ltd Board of Directors (Miami and Perth, Australia, March 5, 2024) Bridgewest Perth Pharma, a global pharmaceutical supply and manufacturing company, with subsidiaries NovaCina and LumaCina, announced today the appointment of Mark W. Womack as a Director of the Board. “We are thrilled to have Mark […]
ADELAIDE, South Australia, and PERTH, Western Australia, Feb. 27, 2024 /PRNewswire/ — BioCina Pty Ltd., a global end-to-end biologics Contract Development and Manufacturing Organisation (CDMO), and NovaCina Pty Ltd., a global fill-and-finish CDMO, announced a strategic partnership to provide integrated drug substance and drug product solutions for biologics developers. This alliance enables BioCina to offer the highest quality fill-and-finish solutions to
Adelaide, South Australia, November 6, 2023, BioCina Pty Ltd., a global end-to-end biologics contract development and manufacturing organization (CDMO), announced the expansion of their partnership with GPN Vaccines Ltd. GPN Vaccines is a biotechnology company developing a proprietary engineered whole-cell vaccine called Gamma-PNTM against Streptococcus pneumoniae. This bacterium is responsible for causing life-threatening infections such
BioCina Expands Partnership with GPN Vaccines Read More »
ADELAIDE, Australia, Oct. 17, 2023 /PRNewswire/ — BioCina Pty Ltd., a global end-to-end biologics contract development and manufacturing organization (CDMO), announced a new partnership with GenomeFrontier Therapeutics AU Pty Ltd., the Australian entity of GenomeFrontier Therapeutics Inc. headquartered in Taiwan, for a project involving development of innovative virus-free chimeric antigen receptor T cell products (CAR-T)
MIAMI and ADELAIDE, Australia, April 27, 2023 /PRNewswire/ — BioCina, a leading contract development and manufacturing organization (CDMO) is pleased to announce that it has been awarded a $5.0m AUD grant under the Federal Government’s Medical Research Future Fund (MRFF) Grants scheme to fund work with its industry partners to develop enabling technologies for manufacture
(MIAMI and ADELAIDE March 14, 2023) BioCina, a leading contract development and manufacturing organization (CDMO) has appointed Mark W. Womack as CEO. Womack will be responsible for the continued growth, commercial strategy and organizational culture of BioCina. This follows the appointment of founding CEO, Ian Wisenberg, to Executive Chairman of BioCina Board of Directors. “Over
Mark W. Womack Joins BioCina as CEO Read More »
(SAN DIEGO and ADELAIDE June 13, 2022) BioCina, a leading contract development and manufacturing organization (CDMO) today announced that the company has expanded its CDMO service offering to include the manufacture of plasmid DNA (pDNA) in a new dedicated GMP suite. The suite is equipped with up to 300 L single use fermentation capacity and
BioCina announces opening of new GMP plasmid DNA manufacturing suite Read More »
(SAN DIEGO and ADELAIDE April 5, 2022) BioCina, a leading contract development and manufacturing organization (CDMO) is pleased to announce that it has been awarded a $3.0m AUD grant under the Federal Government’s Cooperative Research Centres Projects (CRC-P) Grants scheme to fund work with its industry partners to further develop RNA vaccines and therapeutics. The
BioCina awarded Grant to advance RNA vaccines and therapeutics Read More »
(SAN DIEGO and ADELAIDE January 26,2022) BioCina, a leading contract development and manufacturing organization (CDMO) announces the appointment of Rick Hancock, Chairman of the Board. Hancock, with over 35 years of experience in life sciences, has held various board, executive and operational positions, developing expertise in cGMP manufacturing including plasmids, regulatory affairs, R & D,
Rick Hancock named as Board Chairman for BioCina Read More »
(SAN DIEGO and ADELAIDE, November 30, 2021) BioCina, a leading contract development and manufacturing organization (CDMO) specializing in process development and cGMP manufacturing of microbial-based therapeutics and mRNA vaccines announces the official opening of its new biologics manufacturing facility in Adelaide, Australia. The official opening for the research, development and manufacturing biologic plant in Adelaide
